---
layout: post
title: Early Drug Development
categories: 
share: true
comments: true
tag: [Clinical Pharmacology]
---

이전 학기에 Tozer를 마치고 새로운 책으로 Book reading을 시작하게 되었습니다. 아래와 같이 요약하고자 합니다.

[Early Drug Development - Strategies and Routes to First-in-Human Trials by Mitchell N. Cayen](https://www.amazon.com/Early-Drug-Development-First-Human/dp/0470170867)

![](https://images-na.ssl-images-amazon.com/images/I/51mstpfe5qL._SX329_BO1,204,203,200_.jpg)

![](http://www.drugstorenews.com/sites/drugstorenews.com/files/field_main_image/2016-04/NovelNewDrugs_main.jpg)

# Chapter 1. The Drug Discovery and Development Scene

## Introduction

- 신약 개발의 어려운 점 서술.
- NCE (New Chemical Entity)
- "Bigger is Better" philosophy
- Rule of Five (Lipinski) - 5개 이하 hydrogen bon, 10 bond acceptors, < 500kDa
- Hit-to-Lead Identification
- SAR: Structure-activity compounds
- Small molecule to various new entities
- Table 1.1 - Some Optimal Characteristics Evaluated During the Discovery Phase for Orally Administered Drugs
- Toxicogenomics - Possible alternative to animal tox testing
- "Can it replace the animal models?"
- Permeability and transporter assays -> drug uptake into or efflux from the target organ
- PK뿐 아니라 PD 측정하면 이상적일 것이다(Extremely useful).
- EMEA, FDA, MHLW (Japan)

## CRO (Contract Research Organizations)
- CRO를 잘 골라야 한다. 문화를 잘 관찰

# Chapter 2. ADME strategies in lead optimization
- speaker: Park
- date: 2016-10-25
- Lead optimization - several screens to select an NCE with the best overall efficacy, ADME/PK
- in silico adme screening
- data-based modeling
- log P(partition coefficient), log D (log P using buffer at pH7.4) - charge 띈게 많은 것을 고려함.
- basic requirements for successful in silico modeling
- 구조를 입력하면 대사에 대한 정보가 나옴.
- Metabolomics - 대사체를 분석하는 것이 많은 정보를 줄 수 있다.

# Chapter 5. Chemistry, Manufacturing, and Controls
- in vitro pharmacology
- Pre-NCE activities and CMC development
- Crystal forms - Table 5.5
- preformulation
- 특징화, 제제화
- GMP, LBP
- 특징화되어야 한다.
- Toxicology Formulations
    - later Stages of tretm

# Chapter 7. Toxicology Program to Support Initiation of a CLinical Phase I Program For a New Medicine

- Nonclinical safety margin
- 비임상 개발 review시에도 physician이 참가해야 한다.
- Inactive ingredients -> FDA approval.
- Timely Conduct 
- Ames - IND 필수 항목. Regulatory submission of IND.
- if + in Ames -> similar pharmacologic activity and negative in the Ames assay.
- 미국 IND, 영국 CTA, 12-18 months
- 28 days. Maximum duration of dosing that can occur in the human studies
- No observable effect level
- HNSTD - Highest nonsevere toxic dose - NOAEL보다는 좀더 높다. Severe adverse events가 나타나지 않는 최대의 용량을 말하는 것.
- IND - regulatory requirement, guidelines, safety, controlled condition->synthesized. 
- pre-FIH toxicity studies - providing a basis for selection of the initial dose
- 1/10 NOAEL 1/6 non rodent
- Toxicology만 받았는데.. 앞으로는 efficacy 측면에서 효과를 보여야 할지도 모른다.

